Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study

Conclusion: Our study demonstrated that over 90% of TT-DTC patients with unexplained hyperthyroglobulinemia are stratified as being at intermediate to high risk, and RAT using 5.55 GBq of 131I reveals biochemical, functional, or structural disease and yields a non–structurally or –functionally incomplete response in more than 80% patients, suggesting that TT-DTC patients with unexplained hyperthyroglobulinemia are explicit candidates for RAT.

Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Cheng, L., Sa, R., Luo, Q., Fu, H., Jin, Y., Tang, L., Yang, Y., Yu, C., Chen, L. Tags: Clinical Source Type: research